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ABSTRACT
Protein kinase C (PKC) isoforms are being elucidated as an increasingly diverse family of enzymes involved in
the downstream signal transduction and cell function in various types of cells. To date, 11 PKC isoforms have
been identified; they are grouped according to their molecular structure and mode of activation: conventional
PKCs (α, βI, βII, and γ), novel PKCs (δ, ε, μ, θ, and η), and atypical PKCs (ζ, and ιλ). Eosinophils are involved
in the pathogenesis of allergic diseases such as bronchial asthma, pollinosis, and atopic dermatitis as well as in
the inflammatory response to parasitic infections. Recent studies using selective activators and inhibitors of in-
dividual PKC isoforms have revealed that this enzyme is involved in eosinophil dynamics such as cell motility
and other functions. However, the role of PKCs in eosinophil functions has been not wholly understood. In this
review, we have focused upon and summarized the current knowledge regarding the role of PKC isoforms in
eosinophil functions.
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INTRODUCTION
Protein kinase C ( PKC ) is a family of serine
threonine kinases that play key, distinct roles impli-
cated in major cellular functions in a variety of cell
types. The PKC activity was first defined as a histone
kinase activity in the rat brain, which could be acti-
vated by limited proteolysis.1 This kinase could also
be activated by phosphatidylserine (PS) and diacyl-
glycerol (DAG) in a Ca2+-dependent manner as well
as by tumor-promoting phorbol esters such as 4-
phorbol 12-myristate 13-acetate (PMA).2 It has been
elucidated that PKCs play an important role in the
signal transduction pathway in various cells.
Based on the similarity in the primary amino acid
sequence and domain structure, at least 11 PKC iso-
forms have been identified in mammalian tissues to
date . The distinct PKC isoforms are grouped into
three subfamilies: “conventional” or “classical” PKCs
(cPKCs) that include the α, βI, βII, and γ isoforms;
“novel” PKCs (nPKCs) that include the δ, ε, θ, and η
isoforms; and “atypical” PKCs (aPKCs) that include
the ζ and ι isoforms (the mouse homologue of PKC ι
has been named PKC λ).
Eosinophils play pivotal roles in allergic diseases
and responses such as bronchial asthma, allergic der-
matitis, and parasitic infections.3 These cells contrib-
ute to tissue injury and inflammation by the genera-
tion of a number of toxic products in response to vari-
ous proinflammatory mediators such as toxic granule
proteins (e.g., major basic protein (MBP), eosinophil
peroxidase (EPO), eosinophil cationic protein (ECP),
and eosinophil-derived neurotoxin (EDN)), reactive
oxygen species (ROS; e.g., superoxide anion), and
other mediators (e.g., cysteinyl leukotrienes (CysLTs)
and platelet-activating factor (PAF)).
Using selective activators and inhibitors of individ-
ual PKC isoforms, several studies have convincingly
proved that this enzyme is involved in a variety of
eosinophil functions such as cell adhesion,4-7 shape
change , 8,9 chemotaxis , 8 superoxide anion genera-
tion,10-15 degranulation,16-19 and release of other me-
diators.20-23 However, the role of PKCs in eosinophil
functions has not yet been fully elucidated. In this re-
view, we summarize the role of PKC isoforms, par-
ticularly in eosinophil functions.
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Table 1 PKC isoforms and their activators and regulatory domain structures
Subgroup Isoforms Activators Regulatory domain structure
DAG/phorbol ester
binding
C1a C1b C2
P C1a C1b
P C1 Catalytic
domain 
Catalytic
domain 
Catalytic
domain 
PS,＊1
Ca2+, 
DAG,＊2
Phorbol ester
α, βI, βII, γ
PS,
DAG,
Phorbol ester
PIP3, ＊3
PS,
Ceramides
δ, ε, µ, η, θ
ζ, ι /λ
＊1PS, phosphatydilserine;  ＊2DAG, diacylglycerol;
＊3PIP3, phosphatidylinositol-3,4,5-trisphosphate;  ＊4P, pseudosubstrate
Ca2+ binding
P＊4
Novel
PKCs
Conventional
PKCs
Atypical
PKCs
C2-like
STRUCTURE AND PROPERTIES OF PKC
ISOFORMS
PKC isoforms have been classified into three sub-
groups (i.e., cPKCs, nPKCs, and aPKCs) according
to their regulatory properties, which are conferred by
specific domains in the proteins (shown in Table 1).
PKCs are single polypeptide chains with N-terminal
regulatory domains that contain an autoinhibitory
pseudosubstrate domain , two membrane-targeting
modules (termed C1 and C2), and a highly conserved
C-terminal catalytic domain (that contains the C3 and
C4 motifs required for ATPsubstrate binding and
catalytic activity).24-27 The cPKC isoforms contain two
membrane-targeting modules designated as C1 and
C2. The C1 domain of cPKCs contains two cysteine-
rich zinc fingers termed C1a and C1b; 28 the latter is
involved in the binding of DAG and PMA29-31 The C2
domain of cPKCs binds anionic phospholipids in a
Ca2+-dependent manner due to the presence of sev-
eral invariant Ca2+-binding residues in three loops at
one end of the structure.32 Similarly, the nPKC iso-
forms have twin C1 domains and a C2 domain (which
precedes the C1 domain in the case of nPKCs) in
their N-terminal regulatory regions. However, the C2
domain-like sequence of nPKCs lacks side chains
bearing Ca2 +-coordinating acidic residues ; hence ,
nPKCs are maximally activated by DAGPMA and do
not require Ca2+. 33,34 The aPKC isoforms lack a Ca2+-
sensitive C 2 domain and contain only a single
cysteine-rich zinc finger structure that binds neither
DAG nor PMA. 33,35 As a result , neither Ca2 + nor
DAGPMA regulate the aPKC isoforms. On the other
hand, it has been suggested that the activation of
PKC ζ may depend on phosphatidylinositol 3, 4, 5-
trisphosphate (PIP3), which is mainly produced by
phosphatidylinositol 3-kinase (PI3-K). PKC ζ is phos-
phorylated and activated by 3'-PI-dependent protein
kinase 1, which binds with high affinity to PIP3.36
To summarize, the cPKC isoforms (PKCs α , βI ,
βII, and γ) can be activated by Ca2+ andor by DAG
and phorbol esters. The nPKC isoforms (PKCs δ, ε,
θ, and η) are also activated by DAG and phorbol es-
ters but are independent of Ca2+. Finally, the aPKC
isoforms (PKCs ζ and ι) are responsive to neither Ca
2 + nor DAGphorbol esters , while PIP3 has been
shown to activate PKC ζ.
ROLE OF PKC ISOFORMS IN A VARIETY OF
CELL FUNCTIONS
Although most of the PKC isoforms are ubiquitous in
mammalian tissues, some isoforms have a dispropor-
tionate distribution in specific cells, for example, PKC
α in T cells,37 PKC β in B cells,37 PKC γ in the brain
(most abundant in the cerebellum, hippocampus, and
cerebral cortex) , 38 PKC η in epithelial cells , 39 and
PKC θ in T cells and muscle cells.40-42 PKCs are par-
ticularly important signaling mediators in immune
cells.43 For example, PKC β participates in the control
of humoral immune responses and cellular responses
of B cells . 44 PKC ε is involved in the
lipopolysaccharide-mediated signaling in activated
macrophages.45 Further, another report has shown
that the respiratory burst activity in neutrophils was
reduced by the inhibition of p47-kD protein (a compo-
nent of nicotinamide adenine dinucleotide phosphate
(NADPH) oxidase―the enzyme responsible for the
respiratory burst of polymorphonuclear leukocytes
( PMNs ) ) phosphorylation by 1-O-hexadecyl-2-Q-
methylglycerol (cPKC and nPKC inhibitor). As a re-
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Table 2 Efects of PKC inhibitors or activators on eosinophil function
ReferencesSpesiesrelated PKC isoformsEfect of reagentsStimulantFunction
63Humanα, βI, βI, γ, δ, ε↑(Bis I＊2)PAF＊1Adhesion
 5Humanδ↓(Rotlerin)PMA＊3
 7Humanδ ↓(Rotlerin)IL-5＊4
64Humanζ ↓(myristoylated PKC ζ inhibitor)PAF, C5a＊5
 6EquinecPKCs ↓(Go6976)Histamine
 9Humanbroad↓(GF109203, Staurosporine)IL-5Shape change
66Humanbroad→(GF109203)PAF, IL-5Chemotaxis
63Humanα, βI, βI, γ, δ, ε↓(Bis I, myr-ψPKC)PAFSuperoxide generation
64Humanζ ↓(myristoylated PKC ζ inhibitor)PAF
 6Equineδ ↓(Rotlerin)Histamine
19Humanbroad↓(Staurosporine, Calphostin C)SOS＊6Degranulation
74Humanδ ↑(Rotlerin)C5a
64Humanα, βI, βI, γ, δ, ε, ζ↓(myristoylated PKC ζ inhibitor, Bis I)PAF, C5a
17Guinea pigcPKCs, aPKCs↓(PMA)PAF
21HL-60 celsbroad↓(Staurosporine, Bis I)A23187Mediator release
23Humanα, βI, βI, γ, δ, ε↑(Bis I)PAF(ex. CysLTs,＊7 TXB2＊8)
＊1PAF, platelet-activating factor; ＊2Bis I, bisindolylamleimide I; ＊3PMA, 4-phorbol 12-myristrate 13-acetate; 
＊4IL-5, interleukin-5; ＊5C5a, complement component 5a; ＊6SOS, serum-oponized sephadex beads
＊7CysLTs, cysteinyl leukotrienes; ＊8TXB2, thromboxane B2
sult, PKCs appear to play a major role in the regula-
tion of NADPH oxidase. 46
STUDIES ON THE ROLE OF PKC ISO-
FORMS USING GENETICALLY ENGI-
NEERED MICE
Recent studies on PKC isoform-selective knockout
mice have revealed important insights into the func-
tion of individual PKCs in mammals ; these are de-
scribed briefly in the following text. (1) PKC γ, one of
the most prominent PKC isoforms in the brain, has
been shown to be important for the brain functions
involved in learning and memory.47 (2) Lack of PKC
β leads to immunodeficiency due to impaired hu-
moral and B cell responses.44 PKC β also appears to
be critically involved in B cell receptor-mediated sur-
vival signaling for NF-κB activation.48 (3) PKC ε has
been shown to be involved in the regulation of
GABAA receptor function 49 and lipopolysaccharide-
mediated signaling.50 (4) PKC θ appears to be in-
volved in a unique signaling pathway linking T cell
antigen receptor signaling to NF-κB activation in ma-
ture T cells . 51 (5) PKC δ-deficient smooth muscle
cells were shown to be resistant to the apoptosis in-
duced by angiotensin II and endothelin-1.52 In addi-
tion, the loss of PKC δ leads to increased antigen-
induced mast cell degranulation53 and to the preven-
tion of B cell tolerance owing to maturation and dif-
ferentiation of B cells.54 (6) PKC ζ is important for
the regulation of NF-κB transcriptional activity. Con-
sequently, a lack of PKC ζ leads to impaired B cell re-
ceptor signaling, inhibition of cell proliferation and
survival, and defects in the activation of extracellular
signal-regulated kinases (ERK) and the transcription
of NF-κB-dependent genes. 55,56
In contrast to studies on knockout mice, with use
of transgenic mice , in which PKCs were overex-
pressed , the role of individual PKC isoforms was
characterized. For instance, the studies characterized
PKCs α and δ as regulators of glucose transport; 57
PKCs α and θ, calcineurin-induced transactivation; 58
and PKC ζ, RelA (p65, a component of NF-κB) tran-
scriptional activity.59 In addition to previous knowl-
edge, these recent genetic studies suggest that PKC-
related signaling pathways participate in transcrip-
tional control, particularly that of NF-κB in various
cells.
ROLE OF PKCS IN EOSINOPHIL FUNCTION
PKC isoforms are thought to be important regulators
of downstream signaling cascades that control
eosinophil cellular responses . Recently , interesting
findings were obtained using selective activators
andor inhibitors of individual PKC isoforms that
may be involved in eosinophil functions (shown in Ta-
ble 2) . The findings of PKCs related to eosinophil
functions are summarized below.
CELLULAR ADHESION
In the early process of eosinophils activation, circulat-
ing eosinophils roll, tether, and adhere to vascular en-
dothelial cells . The concentration gradient of
chemokines induces eosinophil transmigration
through endothelial gaps and accumulation at the in-
flammatory site. Then, the eosinophils adhere to the
appropriate ligand on the subepithelial cells . 3,60 In
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these processes, cellular adhesion has been shown to
be one of the most critical steps for eosinophil activa-
tion.18 We have previously demonstrated that treat-
ment with an antibody against β2 integrin can almost
completely inhibit not only eosinophil adhesion but
also the degranulation induced by a lipid mediator (e.
g., platelet-activating factor (PAF)), a cytokine (e.g.,
IL-5), or an immunogloblin (e.g. , IgG). 61,62 These
findings suggest that the β2 integrin-dependent cellu-
lar adhesion, particularly αMβ2 (CD11bCD18), that
is induced by the above stimuli through the mem-
brane receptors is critical for the effector functions of
eosinophils.
We have demonstrated the effects of several PKC
inhibitors, including a broad-spectrum PKC inhibitor
such as bisindolylamleimide I (Bis I ; inhibitor of
PKCs α, βI, βII, γ, δ, and ε), peptide 20―28 (inhibitor
of PKCs α and β), and a specific PKC δ inhibitor (rot-
tlerin) or PKC ζ inhibitor (myristoylated PKC ζ in-
hibitor ) , on CD11b expression on the surface of
eosinophils.63,64 The PKC ζ inhibitors did not affect
the spontaneous or PAF- or C5a-induced CD11b ex-
pression in eosinophils to the extent observed with
other PKC inhibitors, while only Bis I enhanced the
PAF-induced CD11b expression , as previously re-
ported.65 This evidence indicates the possibility that
PKC isoforms other than PKCs α, β, δ, and ζ are in-
volved in the PAF- or C5a-induced CD11b expression.
Furthermore, we have shown that the PKC ζ inhibi-
tor attenuated the PAF- or C5a-induced cell adhesion.
63 In addition, Sano and colleagues have shown that
rottlerin blocked the IL-5-induced β 2 integrin-
dependent adhesion of human eosinophils.7 We also
found that rottlerin inhibited the PAF-induced adhe-
sion in human eosinophils (unpublished data). These
results indicate that the β2 integrin-dependent adhe-
sion is also mediated by the activation of a PKC δ or ζ
pathway. Thus, interestingly, it appears that various
PKCs participate in cellular adhesion, probably due to
the differences in stimulants or some experimental
conditions．
SHAPE CHANGE AND CHEMOTAXIS
During the process of recruitment and activation of
eosinophils in the early steps of the immune re-
sponse, eosinophils are stimulated on contact with
chemoattractants ; this results in a change in their
shape, which is a prerequisite for chemotaxis.3 Then,
the eosinophils migrate by chemotaxischemokinesis
to the inflammatory site after being attracted by the
various mediators released from inflammatory cells.
A previous study has reported that Bis I had no effect
on the PAF-induced eosinophil chemotaxis . 66 Re-
cently , another study has shown that inhibitors of
mitogen-activated protein ( MAP ) kinase blocked
both eotaxin- and IL-5-induced eosinophil shape
changes in a dose-dependent manner, although treat-
ment with broad-spectrum PKC inhibitors such as
Bis I or staurosporine resulted in a striking inhibition
of eosinophil shape change induced by IL-5 but not
by eotaxin.9 This data indicated that IL-5 and eotaxin
probably regulate eosinophil shape change via a
largely overlapping signaling pathway through MAP
kinase. However, involvement of PKCs is limited only
to the IL-5 signaling pathway in this study.9
SUPEROXIDE ANION GENERATION
In inflammatory conditions such as asthma, eosino-
phils migrate into the airways and generate highly
toxic ROS, including superoxide anion and hydrogen
peroxide . 65 The superoxide-generating enzyme
NADPH oxidase is a multiprotein complex that com-
prises the membrane-bound cytochrome b558 (a com-
plex of gp91 and p22) and Rap1A and four translocat-
able cytosolic components (p47phox, p67phox, p40phox,
and rac2―a small G protein).67 In our previous study,
the nonspecific PKC inhibitor Bis I was used to de-
tect the PKC isoforms implicated in PAF-activated su-
peroxide anion generation.63 In this study, we found
that 3 μM of Bis I produced significant inhibition of
PAF-induced superoxide anion generation; however,
lower concentrations of Bis I modestly enhanced the
superoxide anion generation (enhancement was not
significant). Another study demonstrated that three
PKC inhibitors―staurosporine , Ro318220, and Go
6983―inhibited the PMA-induced superoxide anion
generation in human eosinophils.68 These data sug-
gest that PKCs are involved in the pathway that con-
tributes to superoxide anion generation from eosino-
phils . On the other hand , Bankers-Fulbright et al.
showed that PKCs α, βI, βII, γ, δ, and ζ are constitu-
tively expressed in human eosinophils, and a PKC δ
inhibitor blocked the IL-5- or LTB4-mediated superox-
ide anion generation, indicating that PKC δ regulates
the IL-5- or LTB4-evoked NADPH oxidase activity in
eosinophils.69 By using the PKC δ inhibitor rottlerin,
we also showed that PKC δ is involved in the super-
oxide generation from PAF-stimulated eosinophils.70
Further, we have found that PAF activates two dis-
tinct effector pathways leading to superoxide anion
generation; one is a pertussis toxin (PTX)-sensitive
pathway that leads to immediate and transient
adhesion-independent activation, and the other is a
PTX-resistant pathway that leads to late and extended
adhesion-dependent activation. We have discovered
that the latter pathway evokes substantial superoxide
anion generation and is mediated by PI3-K.71 In addi-
tion, previous reports have shown that PI3-K is essen-
tial for PKC δ 72 and PKC ζ activation. 73 Taken to-
gether , these observations and our present results
suggest that substantial stimulus-induced superoxide
anion generation is modulated by PKCs ζ and δ ,
which might be activated by PI3-K. In addition, our
recent study has shown that a PKC ζ inhibitor sup-
pressed the PAF- or C5a-induced superoxide anion
generation in a dose-dependent manner.64 We com-
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Fig. 1 The possible role of PKC isoforms in eosinophil function and its signal-
ing pathway. Receptor-mediated stimulation by mediators induce β2 integrin ex-
pression on the eosinophil surface and a conformational change in the integrin 
molecule ( ‘ inside-out’ signaling). Protein kinase C (PKC) isoforms other than 
PKCs α, β, δ, and ζ might be involved in the downregulation of the PAF-in-
duced β2 integrin expression. Clustering and/or multimerization of αMβ2 result-
ing from the ‘ inside-out’ signaling is probably promoted by PKCs δ and ζ; both 
these isoforms are activated by phosphatidylinositol 3-kinase (PI3-K). The 
αMβ2-ligand interaction ignites the ‘ outside-in’ signaling, for instance, phospho-
rylation of tyrosine kinase (PTK) folowed by activation of phospholipase C 
(PLC). Activated PLC catalyzes the formation of DAG, which activates cPKCs 
and nPKCs. Another product of PLC, inositol triphosphate (IP3), which induces 
the release of Ca2+ from the intracelular stores, is involved in the activation of 
cPKCs. The αMβ2-ligand interaction evokes the activation of PI3-K, which can 
contribute to the activation of PKCs δ and ζ. Eventualy, various eosinophil ef-
fector functions such as superoxide anion generation might be induced, at 
least, by PKCs β, δ, and ζ, and degranulation, by PKC ζ. Alternatively, a ligand 
coupled to its receptor stimulates the G protein; this is folowed by the activation 
of second messengers and the activation of PKC isoforms such as PKC δ. This 
signal might cause a shape change, chemotaxis, and mediator release 
(cysLTs, PAF, etc) or eicosanoid production that is probably independent of cel-
lular adhesion and outside-in signaling.
Receptor
αM
PLC
DAG
Ligand
Degranulation
ζ
cAMP
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PTK
PKC
δ
PLC
DAG
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Promotion
Suppression
Stimulant Superoxide  generation
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pared this effect with those produced by other PKC
inhibitors such as Bis I, peptide 20―28, and rottlerin.
As a result, a significant difference in the IC50 values
was observed with respect to the effects of the PKC
inhibitors on eosinophil superoxide anion generation;
this suggests that the involvement of PKC isoforms
might depend on the stimulant . Furthermore , we
have demonstrated that the interception of actin as-
sembly with cytochalasins, which are inhibitors of ac-
tin polymerization , resulted in the inhibition of
eosinophil shape changes as well as the suppression
of translocation of PKCs βII, δ, and ζ to beneath the
cell membrane; this suggests that the cytoskeleton-
related translocation of PKCs plays a critical role in
the superoxide anion generation in adherent human
eosinophils.65 This evidence suggests that PKC δ or ζ
and PKC βII activate the stimuli-induced substantial
superoxide anion generation, and the translocation of
PKCs βII, δ, and ζmight be responsible for the super-
oxide anion generation in eosinophils.
DEGRANULATION
Similar to superoxide anion generation , degranula-
tion accompanied by the release of toxic granule pro-
teins is thought to be one of the major eosinophil ef-
fector functions and may be related to the pathogene-
sis of allergic diseases such as bronchial asthma. The
relationship between eosinophil degranulation and
Allergology International Vol 55, No3, 2006 www.jsaweb.jp 249
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PKCs was investigated in several studies.19,64,74 In a
previous study, the ECP release induced by serum-
opsonized Sephadex beads (SOS) was inhibited by
nonspecific PKC inhibitors such as staurosporine or
calphostin C.19 We also showed that a specific PKC ζ
inhibitor attenuated the PAF- and C5a-induced EDN
release from eosinophils . 64 In contrast , another re-
port has demonstrated that the activation of PKC δ by
PMA can stimulate cAMP production through
adenylate cyclase (AC) and that there was a good cor-
relation between the increase in intracellular cAMP
and the inhibition of degranulation in human eosino-
phils.74 This report has indicated that PKC δ activa-
tion by PMA was negatively implicated in the de-
granulation occurring via stimulation of cAMP pro-
duction. We also found that high doses of rottlerin en-
hanced the PAF- or C5a-induced degranulation in hu-
man eosinophils (unpublished data).
Furthermore, we have shown that the inhibition of
PKC by 3 μM of Bis I led to a reduction in the PAF-
induced degranulation from human eosinophils; how-
ever, lower concentrations of Bis I enhanced the de-
granulation.63 This result was similar to that obtained
with PAF- or C5a-induced superoxide anion genera-
tion and degranulation.63,64 These responses suggest
that PKCs have dual modes of regulation of the PAF-
evoked signaling pathway in human eosinophils.
MEDIATOR RELEASE
Eosinophils release physiologically active substances
such as PAF, cysteinyl leukotrienes (CysLTs), and
thromboxane B2 (TXB2), which are chemical media-
tors of inflammation. A previous report showed that
staurosporine or Bis I prevented the inhibition of
CysLT synthesis in an eosinophilic strain of HL-60
cells stimulated by the calcium ionophore A23187.21
In contrast , the effect of PKC activation on CysLT
synthesis and the formation of prostaglandin E2 and
TXB2 was elevated after PMA treatment; this effect
was prevented by staurosporine. These results indi-
cate that PKCs also play a role in lipid mediator re-
lease.
PARTICIPATION OF PKC ISOFORMS IN EOSINO-
PHIL FUNCTIONS AND ITS SIGNALING PATH-
WAYS
Based on the above-mentioned evidence, we formu-
lated a hypothesis for the possible intracellular signal-
ing mechanism and the role of PKC isoforms in the
regulation of eosinophil effector functions (shown in
Fig. 1). Receptor-mediated stimulation via a receptor-
coupled GTP-binding protein (G protein) induce the
expression of β2 integrin on the eosinophil surface
and a conformational change in the integrin mole-
cules, i.e., the so-called “inside-out” signaling.60,75 In
this process, some PKC isoforms other than PKCs α,
β, δ, and ζmight be involved in the downregulation of
PAF-induced β2 integrin expression.63,64 Moreover, a
report recently suggested that a signaling cascade
through PI3-K and PKC δ is involved in the IL-5-
induced β2 integrin-dependent adhesion of human
eosinophils.76 The clustering andor multimerization
of αMβ2 is followed by its focal adhesion to appropri-
ate ligand(s). Several PKC isoforms such as PKCs δ
and ζ are thought to participate in the cellular adhe-
sion of αMβ2 to the ligand.7,63 Once the clustering or
multimerization of αMβ2 occurs at the sites of focal
adhesion, the “outside-in” signaling is triggered in
the cells. Previously, we have shown that the engage-
ment of αMβ 2 induced the activation of tyrosine
kinase (PTK).62,75 It is assumed that PTK activation is
followed by the phosphorylation of several proteins,
including phospholipase C (PLC).60 Activated PLC
catalyzes the formation of DAG , which modulates
cPKCs and nPKCs, and inositol triphosphate ( IP3)
from PIP2. IP3 induces the release of Ca2+ from the in-
tracellular stores ; this released Ca2 + together with
DAG is involved in the activation of cPKCs. On the
other hand, activated PI3-K produces PIP3, which can
contribute to the activation of PKC ζ.36 Furthermore,
the PI3-K activity is essential for PKC δ activation.72
Subsequently, the activation of PKCs might positively
regulate the eosinophil functions, at least, by the in-
volvement of PKCs βII, δ, and ζ in superoxide anion
generation and of PKC ζ in degranulation. Alterna-
tively, a ligand coupled to its receptor stimulates the
G protein; this is followed by the activation of second
messengers and the activation of PKC isoforms such
as PKC δ. This signal might cause a shape change,
chemotaxis, and mediator release (cysLTs, PAF, etc.)
or eicosanoid production that is probably independ-
ent of cellular adhesion and the outside-in signaling.
In conclusion, although a great deal of evidence is
being accumulated on the role of PKCs in eosinophil
functions, further studies are needed to clarify the ex-
tent of their involvement using more specific inhibi-
tors andor activators of individual isoforms, which
would be developed in the near future. The clarifica-
tion of the precise role of PKCs in human eosinophils
would enable the development of a pioneering strat-
egy for the treatment of allergic diseases such as
bronchial asthma.
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